Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 9 April 2025 - 9:27

Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2902

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters